Bevacizumab-induced nasal septum perforation

被引：35

作者：

Fakih, Marwan G.

Lombardo, Jeffrey C.

机构：

[1] Roswell Pk Canc Inst, Dept Med, Div Med Oncol, Buffalo, NY 14263 USA

[2] Roswell Pk Canc Inst, Dept Pharm, Buffalo, NY 14263 USA

来源：

ONCOLOGIST | 2006年 / 11卷 / 01期

关键词：

D O I：

10.1634/theoncologist.11-1-85

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：85 / 86

页数：2

共 5 条

[1]

Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S

[2] Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis [J].

Hicklin, DJ ;

Ellis, LM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1011-1027

[3] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[4]

HURWITZ H, 2004, J CLIN ONCOL, V22, P3702

[5] INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS SUPPRESSES TUMOR-GROWTH INVIVO [J].

KIM, KJ ;

LI, B ;

WINER, J ;

ARMANINI, M ;

GILLETT, N ;

PHILLIPS, HS ;

FERRARA, N .

NATURE, 1993, 362 (6423) :841-844

← 1 →